Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The future of PARP inhibitors in metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.19
Views: 283

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA

Prof Debu Tripathy speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the current landscape of PARP inhibitors and the future for this type of targeted therapy.

He discusses the action of these drugs along with the issue of resistance, in which some tumours are able to mutate the BRCA gene back to the non-mutated form.

Prof Tripathy notes that further understanding is needed to understand these mechanisms of resistance along with combining other types of therapy, such as immunotherapy with PARP inhibitors.

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation